OncoMatch/Clinical Trials/NCT06959732

Zanubrutinib Combined With G-CVP in Previously Untreated FL

Is NCT06959732 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies zanubrutinib, obinutuzumab,combined with CVP for follicular lymphoma ( fl).

Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06959732Data as of May 2026

Treatment: zanubrutinib, obinutuzumab,combined with CVP — The goal of this clinical trial is to learn the efficacy and safety of zanubrutinib in combination with G-CVP in previously untreated follicular lymphoma patients The main questions it aims to answer are: (1) Efficacy and safety of patients receiving zanubrutinib, obinutuzumab combined with cyclophosphamide, vincristine, and prednisone (CVP) regimen. (2) The difference in efficacy of patients with different minimal residual disease (MRD) status after treatment. Participants will receive zanubrutinib combined with G-CVP, maintenance therapy will be determined by the MRD status after treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Biomarker criteria

Required: MS4A1 overexpression (CD20-positive)

Histologically confirmed CD20-positive FL

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

ANC < 1.5 × 10⁹/L, platelets < 75 × 10⁹/L, or hemoglobin < 70 g/L (unless due to bone marrow involvement by lymphoma)

Kidney function

serum creatinine > 2 × ULN or creatinine clearance < 60 mL/min (unless due to lymphoma involvement)

Liver function

serum direct/indirect bilirubin, ALT, AST > 2 × ULN (unless due to lymphoma involvement)

Abnormal liver or kidney function, defined as: serum direct/indirect bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), or serum creatinine > 2 × upper limit of normal (ULN); creatinine clearance < 60 mL/min (unless due to lymphoma involvement); Absolute neutrophil count (ANC) < 1.5 × 10⁹/L, platelets < 75 × 10⁹/L, or hemoglobin < 70 g/L (unless due to bone marrow involvement by lymphoma)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify